CClinicalTrials.gg
CompletedNCT03428880QLBUpdated Feb 14, 2018

Ultrasound Guided QLB III Versus Intrathecal Morphine for Analgesia After Cesarean Section

A Phase 4 interventional study of Morphine and Quadratus lumborum block in Block, sponsored by University Tunis El Manar. Completed at 2 sites in Tunisia. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-02-14.

Sponsored by University Tunis El Manar · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Subarachnoid morphine (SAM) is the gold standard for treating postoperative pain after cesarean delivery (CD) but it has undesirable side effects, that's why the aim of our study is to identify whether ultrasound-guided Quadratus lumborum block type 3, a new regional anesthetic technique that blocks the abdominal wall neural afferents, can provide at the same time better postoperative analgesia after CD with less side effects

Read the detailed description

In this prospective double blinded randomized study,120 parturients undergoing cesarian delivery via a Pfannenstiel incision and who agreed to spinal anesthesia were randomly scheduled to receive either a SAM (group SAM, n=60) or a Quadratus lumborum block type 3 (group QLB, n=60).Spinal anesthesia was initiated with hyperbaric Bupivacaïne 0.5% 10 mg, 0,005 mg SUFENTANIL MEDIS and 0.1 mg morphine in the SAM group and with Bupivacaïne 0.5% 10 mg, 0,005 mg SUFENTANIL MEDIS and 1 ml normal saline in group QLB.

After surgery, bilateral QLB block type 3 was performed with the patient in lateral position using bupivacaine 0.25% , 20 mL on each side in group QLB and 20 ml normal saline in group SAM.

Postoperative analgesia for the first 24 hours consisted of a patient controlled analgesia with IV morphine only. If necessary breakthrough pain was treated by 01 g paracetamol intravenously by the same doctor in charge of taking the values of the visual analogue scale.

Patients were assessed postoperatively in the postanesthesia care unit (time 0 hours) and at 2, 4, 6, 12 and 24 hours.

Visual analogue scale (VAS) for pain at rest and during the palpation of the uterine globe was noted.

The primary outcome measure was the total dose of morphine over 24 hours delivered by a patient-controlled analgesia system at predetermined intervals.

Secondary outcomes were visual analogue scale (VAS) for pain at rest and on the palpation of the uterine globe ,heart rate, blood pressure, itching, nausea, pruritus, vomiting and sedation.

02

Conditions studied

  • Block

Keywords

  • quadratus lumborum block
  • cesarean section
  • spinal morphine
  • ultrasound guidance
03

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • ASA I/II.
  • Normal singleton pregnancy with a gestation of at least 37 weeks.

Exclusion criteria

Exclusion Criteria:

  • Heart disease
  • Coagulopathy
  • pre-eclampsia
  • BMI> 40
  • Patient refusal to undergo the Quadratus lumborum block.
  • Allergy to local anesthetics
04

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
120 participants (actual)

Study arms

  • Active comparator
    spinal morphine

    intrathecal morphine with 10 mg bupivacaine, 5 gamma sufenta and 100 gamma morphine. Intervention: In the end of surgery a QLB block is done with 20 ml of normal saline per side.

    Drug: Morphine

  • Active comparator
    quadratus lumborum block

    intrathecal anesthesia with10 mg bupivacaine, 5 gamma sufena and 1 ml normal saline. Procedure : a quadratus lumborum block is done with 20 ml of bupivacaine 0,125% per side.

    Drug: Quadratus lumborum block

Interventions

  • DrugMorphine

    spinal morphine is done before cesarean section

    Also known as: spinal morphine

  • DrugQuadratus lumborum block

    a US Block QLB is done after surgery

    Also known as: QLB

05

What researchers measure

Primary outcomes

  1. Total morphine consumption over 24 hours postoperatively

    Total IV morphine used when started postoperatively using a PCA with morphine in the post anesthesia care unit until 2' hours posteratively.

    Time frame: Arrival to post anesthesia care unit until 24 hours posteratively

Secondary outcomes

  1. Time to first analgesic demand using PCA pump with morphine

    recording the exact time to first analgesic demand by using the PCA with Morphine

    Time frame: Arrival to post anesthesia care unit until 24 hours posteratively

  2. Visual analog scale (VAS) pain scores at rest and during the palpation of the uterine globe

    At predetermined intervalls, visual analog scale (VAS) pain scores at rest and at the palpation of the uterine globe were noted.

    Time frame: Arrival to post anesthesia care unit until 24 hours posteratively

  3. Time to first deambulaton after surgery

    After surgery, time when the patient was able to move from bed was noted.

    Time frame: Arrival to post anesthesia care unit until 24 hours posteratively

06

Study locations

2 sites
  • Tunis maternity and neonatology center, minisetry of public health
    Tunis, 1007, Tunisia
  • Tunis maternity and neonatology center,
    Tunis, 1007, Tunisia
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03428880
Lead sponsor
University Tunis El Manar
Responsible party
Ben marzouk Sofiene (MD, assistant professor, University Tunis El Manar) — Principal investigator
First posted
Feb 12, 2018
Start date
Feb 15, 2017
Primary completion
Sep 30, 2017
Completion
Oct 20, 2017
Last update
Feb 14, 2018

Study contacts

Hayene Maghrebi, Professor
study chair · tunis maternity center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion